Side-by-side comparison of the two widely studied GRPR radiotracers, radiolabeled NeoB and RM2, in a preclinical setting.

ABSTRACT:

Introduction

NeoB and RM2 are the most investigated gastrin-releasing peptide receptor (GRPR)-targeting radiotracers in preclinical and clinical studies. Therefore, an extensive side-by-side comparison of the two radiotracers is valuable to demonstrate whether one has advantages over the other. Accordingly, this study aims to compare the in vitro and in vivo characteristics of radiolabeled NeoB and RM2 to guide future clinical studies.

Method

The stability of the radiolabeled GRPR analogs was determined in phosphate buffered saline (PBS), and commercially available mouse and human serum. Target affinity was determined by incubating human prostate cancer PC-3 cells with [¹⁷⁷Lu]Lu-NeoB or [¹⁷⁷Lu]Lu-RM2, + / - increasing concentrations of unlabeled NeoB, R

SUBMITTER: Damiana TST 

PROVIDER: S-EPMC10611828 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature